Navigation Links
Intercell to Begin Phase II JE Vaccine Trials in India

Austrian biotech major, Intercell and its partner Hyderabad-based Biological E. Ltd. announced that they have obtained regulatory clearance to start// a pediatric phase II clinical trial for Intercell’s novel Japanese Encephalitis vaccine in India.

The randomized and controlled study aims to demonstrate the dose, safety and immunogenicity of Intercell’s JE vaccine compared to a locally produced mouse-brain Japanese Encephalitis vaccine.

The study, which will start in late April/early May, will enroll children at the age of one to three years. It is the first step towards the licensure of a new cell culture derived product in Asia, which is expected for late 2008/early 2009.

Mr Gerd Zettlmeissl, Chief Executive Officer of Intercell, said, “We have clearly defined a straight forward development process for our Japanese Encephalitis vaccine to enter endemic markets. It is our priority to make the vaccine, which is based on proven and safe technology, also available for the population and especially the children in endemic regions.”

Mr Vijay Kumar Datla, Chairman and Managing Director of Biological E. Ltd said, "We believe that this is a very important milestone in our endeavor to bring a safe and efficacious vaccine to endemic regions."

Source: BioSpectrum
SR/M
'"/>




Page: 1

Related medicine news :

1. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
2. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
3. Cancer Begins With Epigenetic Changes: Study
4. Learning About Healthy Diet Choices Begins At Schools
5. China Begins Human Trials For HIV/AIDS Drug
6. Pilot Study to Test Effect of Mobile Phone Transmissions On Skin To Begin In Finland
7. Preparation for Culling Begin at Belghat, Rajangaon and Dhaamnia
8. Make-Up Tips For Beginners
9. Jalgaon: Third Phase Of Culling Operations Begin
10. Human Bird Flu Vaccine Trials Begin In Russia
11. Administration of Fish Drug for Asthma Patients Begins in Andhra
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: